ClinicalTrials.gg
CompletedNCT07396506Updated Feb 9, 2026

Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions

An interventional study of Dronedarone Hydrochloride Tablets and MULTAQ® (Dronedarone Hydrochloride Tablets) in Atrial Fibrillation (AF), sponsored by Shandong New Time Pharmaceutical Co., LTD. Completed at 1 site in China. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Shandong New Time Pharmaceutical Co., LTD (part of Lunan Pharmaceutical Group) · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jun 2023, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
21st of 26
51 · median 164
Started
2023
with 1 other
No phase
5 of 26
none open now
Registered
25th of 26
by date
Lead sponsor
2 of 26
Shandong New Time Pharmaceutical Co., LTD

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 21st largest by enrollment, is one of 2 that started in 2023, is one of 5 with no phase, and was the 25th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

The test formulation of Dronedarone Hydrochloride Tablets (400 mg) is bioequivalent to the reference formulation (MULTAQ®) in healthy Chinese subjects under fasting conditions.

Read the detailed description

This is a single-center, randomized, open-label, single-dose, three-period, partially replicated crossover study designed to evaluate the bioequivalence and safety of a generic formulation versus the reference formulation of Dronedarone Hydrochloride Tablets (400 mg) in healthy Chinese male subjects under fasting conditions. A total of 51 eligible subjects are planned to be enrolled.

Venous blood samples are collected for the determination of plasma concentrations of dronedarone and its metabolite N-desbutyl dronedarone. In each study period, samples are taken at pre-dose (0 h) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48, and 72 h post-dose.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects who voluntarily participate and provide written in accordance with Good Clinical Practice (GCP) guidelines.
  2. Age ≥ 18 years.
  3. Body weight ≥ 50.0 kg and (BMI) between 19.0 and 26.0 kg/m² (inclusive).
  4. In good health as determined by comprehensive medical history, physical examination, and laboratory tests.
  5. Able to comply with the study protocol and scheduled visits.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormalities in physical examination, vital signs, 12-lead , cardiac ultrasound, or laboratory tests (including hematology, blood biochemistry, urinalysis, virology serology, and coagulation function).
  2. History or presence of severe cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immune, dermatological, neurological, or psychiatric diseases. Specific exclusions include: renal insufficiency, heart failure, stroke, permanent atrial fibrillation, second- or third-degree atrioventricular block or sick sinus syndrome, bradycardia (heart rate \< 50 bpm), prior amiodarone-associated hepatotoxicity or pulmonary toxicity, hypokalemia, hypomagnesemia, or family history of long syndrome.
  3. History of specific allergies (e.g., asthma, urticaria, eczema), allergic constitution (allergy to two or more drugs or substances like milk/pollen), or known to dronedarone, its components, or related compounds.
  4. Major trauma or significant blood loss within 3 months prior to screening.
  5. History of drug abuse within the past 5 years or positive urine drug screen.
  6. Difficulty with blood sampling, needle phobia, or intolerance to venipuncture.
  7. Positive alcohol breath test at screening.
  8. Excessive alcohol consumption (>14 units per week; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine) within 3 months prior to screening, or unwillingness to abstain from alcohol during the study.
  9. Excessive consumption of tea, coffee, or caffeine-containing beverages (>8 cups per day; 1 cup = 250 mL) within 3 months prior to screening, or consumption of any alcohol, caffeine, or xanthine-rich products (e.g., coffee, strong tea, chocolate, cola, grapefruit) within 48 hours prior to dosing.
  10. Inability to comply with a standardized diet (e.g., intolerance to the standard meal) or dysphagia.
  11. Smoking ≥5 cigarettes per day within 3 months prior to screening or unwillingness to refrain from smoking during the study.
  12. Use of any medication (prescription, over-the-counter, herbal, or supplements) within 14 days prior to screening.
  13. Use of any medication known to interact with dronedarone within 1 month prior to screening, including: QT-prolonging drugs, digoxin, calcium channel blockers, CYP2D6 substrates, potent inhibitors, CYP3A inducers, statins, and narrow therapeutic index CYP3A substrates (e.g., dabigatran etexilate, warfarin).
  14. Vaccination within 1 month prior to screening or planned vaccination during the study.
  15. Participation in any other clinical trial within 3 months prior to screening.
  16. Blood donation or significant blood loss (≥400 mL in total) within 3 months prior to screening.
  17. Male subjects (or their partners) planning pregnancy from 2 weeks prior to screening until 3 months after study completion, or unwilling to use a medically acceptable non-pharmacological method during the study.
  18. Any other condition considered by the investigator as unsuitable for participation or voluntary withdrawal.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Dronedarone Hydrochloride Tablets

    Healthy male subjects will be randomized to one of three treatment sequences (A, B, or C) to receive single oral doses of the Test and Reference formulations under fasting conditions, according to a three-period, partially replicated crossover design with a 10-day washout period between each period.

    Drug: Dronedarone Hydrochloride Tablets

  • Active comparator
    MULTAQ®

    Healthy male subjects will be randomized to one of three treatment sequences (A, B, or C) to receive single oral doses of the Test and Reference formulations under fasting conditions, according to a three-period, partially replicated crossover design with a 10-day washout period between each period.

    Drug: MULTAQ® (Dronedarone Hydrochloride Tablets)

Interventions

  • Test Product. Manufacturer: Shandong New Time Pharmaceutical Co., Ltd. Dosage Form/Strength: 400 mg tablet Administration: Single oral dose of 400 mg (1 tablet).

  • Reference Product. Manufacturer: Sanofi-Aventis U.S. LLC Dosage Form/Strength: 400 mg tablet Administration: Single oral dose of 400 mg (1 tablet).

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Evaluation of Peak Plasma Concentration (Cmax)

    Time frame: 72 hours post-dose in each period

  2. Area under the plasma concentration versus time curve (AUC) 0-t

    plasma concentration-time curve from zero to the time of the last measurable time point t

    Time frame: 72 hours post-dose in each period

  3. Area under the plasma concentration versus time curve (AUC)0-∞

    area under the plasma concentration-time curve from zero to infinity

    Time frame: 72 hours post-dose in each period

Other outcomes

  1. maximum plasma concentration (Tmax)

    time to reach the maximum plasma concentration after drug administration (Tmax)

    Time frame: 72 hours post-dose in each period

  2. Incidence of Treatment-Emergent Adverse Events

    Collection of adverse events

    Time frame: 36 days

07

Study locations

1 site
  • Jiangxi Cancer Hospital & Institute (The Second Affiliated Hospital of Nanchang Medical College)
    Nanchang, Jiangxi 330029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jul 2023, 1 month.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 1 month is below that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 9, 2026
StartActual
Jun 5, 2023
Primary completionActual
Jul 10, 2023
CompletionActual
Jul 10, 2023
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07396506
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jun 5, 2023
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Last update
Feb 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion